TrialBritish journal of cancer2018

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).

Baohui Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.